Bill Gates praises Australia’s pandemic response, says vaccine could have rich countries 'back to normal' by late 2021

0
34

“South Korea, Australia – because this is an exponential event, a little bit of intelligence early on makes a huge difference,” he said.

COVID-19 vaccines developed by Pfizer/BioNTech and AstraZeneca/Oxford University are two of the leading candidates in the race to be first to get regulatory approval in the West.

World Health Organisation chief Tedros Adhanom Ghebreyesus said on Tuesday that a vaccine against COVID-19 may be ready by the end of the year.

Gates, who made a fortune from Microsoft, has since given $US36 billion ($50 billion) to the Bill & Melinda Gates Foundation, which aims to tackle extreme poverty and poor healthcare.

Last month the foundation signed an agreement with 16 pharmaceutical companies, which Gates said committed them to scaling up manufacturing at an unprecedented speed, and making sure that approved vaccines reach broad distribution as early as possible.

Vaccine race

Russia has pushed ahead with its COVID-19 vaccine with mass public vaccinations alongside the main human trial, raising concerns among some observers that it was prioritising national prestige over solid science and safety.

Loading

“We’re also talking with Russia and China,” Gates said. “None of their vaccines are in a Phase III trial with a highly regarded regulator overseeing that trial.”

Gates said that from a scientific point of view the Russian and Chinese vaccines were perfectly valid projects but the absence of a well-respected Phase III study could limit their attractiveness outside their respective countries.

“The Western companies are further ahead on doing these Phase III studies and so if those come out well and they’re offered at low cost, I doubt there’ll be a lot of Russian or Chinese vaccines going outside of those countries,” he said.

Gates added that in the United States people should be thinking about ways to reduce hesitancy about having a COVID-19 vaccine when one is ready.

“You know, here in the US, we should already be thinking about which voices will help reduce the hesitancy. And so we can get a level of vaccination that really has a chance of stopping (it).”

Reuters

Business Briefing

Start the day with major stories, exclusive coverage and expert opinion from our leading business journalists delivered to your inbox. Sign up for the Herald‘s here and The Age‘s here.

Most Viewed in Business

Loading

A Global Asset Management Seoul Korea Magazine

This post was originally published on this site